IDH
| 货号 | 产品名 | CAS号 | 信息 |
|---|---|---|---|
| FB12130 | Vorasidenib | 1644545-52-7 | Vorasidenib is an isocitrate dehydrogenase (IDH) inhibitor. |
| FB07000 | Mutant IDH1-IN-2 | 1429176-69-1 | Mutant IDH1-IN-2 is an inhibitor of mutant isocitrate dehydrogenase (IDH) proteins, with IC50 of in LS-MS biochemical assay, IC50 of 16.6 nM in fluorescence biochemical assay. |
| FB06999 | Mutant IDH1-IN-1 | 1355326-21-4 | Mutant IDH1-IN-1 is a potent mutant IDH1 R132H inhibitor with IC50 < 0.1 μM. |
| FB03203 | Mutant IDH1 Inhibitor | 1429180-08-4 | Mutant IDH1 inhibitor is a potent mutant IDH1 R132H inhibitor with IC50 of < 72 nM. |
| FB13164 | IDH-305 | 1628805-46-8 | IDH-305 is a selective inhibitor of IDH1 R132H and R132C with IC50 of 18 and 28 nM, respectively. |
| FB08521 | Enasidenib | 1446502-11-9 | Enasidenib is a selective mutant IDH2 enzyme inhibitor with IC50 of 12 nM. |
| FB16452 | DS-1001b | 1898207-64-1 | DS-1001b is a novel selective mutant IDH1 inhibitor with antitumor activity. |
| FB00151 | D-alpha-Hydroxyglutaric Acid Disodium | 103404-90-6 | D-alpha-Hydroxyglutaric Acid Disodium is a multiple-target inhibitor of KDM4A and α-Ketoglutarate(α-KG)-dependent dioxygenase, as well as an NF-κB activator. |
| FB10919 | BAY 1436032 | 1803274-65-8 | BAY 1436032 is a potent, selective and orally available inhibitor of mutant Isocitrate Dehydrogenase 1 (mIDH1). |
| FB00524 | AGI-6780 | 1432660-47-3 | AGI-6780 is a selective inhibitor of IDH2/R140Q mutant with IC50 value of 23 nM, |
| FB00689 | AGI-5198 | 1355326-35-0 | AGI-5198 is a potent and selective inhibitor of IDH1 R132H and R132C mutants with IC50 values of 0.07 and 0.16 µM, respectively, but not wild-type IDH1, wild-type IDH2, or IDH2 mutants. |
| FB08116 | AG-120 Racemate | 1448346-63-1 | AG-120 Racemate is the racemate form of AG-120 with no activity. |
| FB06998 | AG-120 | 1448347-49-6 | AG-120 is a first-in-class mutant IDH1 inhibitor. |
| FB10365 | (R,S)-Ivosidenib | 2070009-31-1 | (R,S)-Ivosidenib is an inhibitor of isocitrate dehydrogenase (IDH1). |